The Dr. Stanley C. Marinoff Vulvodynia Career Development Award was created to enable junior medical faculty to pursue an interest in improving the health care of women with vulvodynia. This $7500 award may be used (i) to create or enhance a vulvar pain clinic, especially in underserved areas, or (ii) for a clinically relevant research project. It is our hope that this award will attract more junior medical professionals into the vulvodynia field.
The award is open to all medical professionals beginning a career in this field or pursuing an advanced degree related to vulvodynia. Investigators who have already received vulvodynia-specific grant support from the National Institutes of Health or the Canadian Institutes of Health Research (or similar funding organization) are not eligible. Likewise, those who have published more than one original article on vulvodynia in a peer-reviewed scientific journal are not eligible. If the applicant is affiliated with a university, he/she can have a clinical or full-time faculty appointment up to the level of assistant professor.
Recipients of the Career Development Award receive $7,500. The applicant's institution is encouraged to contribute matching funds, or at least a portion of the amount. All NVA grants, including the Marinoff award, may be spent only on direct project costs. NVA does not permit any amount of the award to be spent on overhead or indirect costs.
If you are interested in applying, at your earliest convenience, please send an email to Phyllis Mate at firstname.lastname@example.org that includes a brief (1-2 paragraph) summary of your proposed project goals and objectives by April 10, 2017. Once we have received this information from you, Michelle Living will email you a full application to complete and submit by May 15, 2017.
We welcome correspondence about potential projects. To discuss your proposal, please contact Phyllis Mate via email (email@example.com) or leave a message at (301) 299-0775.
The NVA is seeking research proposals on the causes and treatment of vulvodynia. We are especially interested in studies that may shed light on underlying pathophysiological mechanisms.
If you are interested in applying, please send an email to Phyllis Mate (firstname.lastname@example.org) by Tuesday, March 21, 2017 that includes a brief (1-2 paragraph) summary of your proposed study's design and objectives. Once we have received this information from you, we will email you a full application to complete and submit by Monday, May 1, 2017.
The maximum grant amount is between $25,000 and $30,000 and we require confirmation that all funds will be applied to direct research costs, not institutional costs. If you've previously applied and/or received grant support from the NVA, you are still eligible to apply. Summaries of studies that NVA has funded to date can be viewed on NVA's web site.
We welcome correspondence about potential projects. To discuss your proposal, please contact Phyllis Mate via email (email@example.com).
Nominate a researcher for the prestigious Eugene J. Van Scott Award for Innovative Therapy of the Skin and Phillip Frost Leadership Lecture. Offered by the American Academy of Dermatology and made possible through a generous contribution from Phillip Frost, MD, FAAD, this Award and Lecture is given in recognition of significant contributions toward an innovative therapy of the skin, hair and/or nails. Open to all; not restricted to a dermatologist.
AMAG Pharmaceuticals, Inc. has awarded $300,000 in grants—an increase of $150,000 from last year—to fund research aimed at reducing premature birth and improving the health of neonates and infants in the United States through its Prematurity Research Grants Program. The American College of Obstetricians and Gynecologists congratulates the 2016 recipient principal investigators:
Mir Basir, M.D., an associate professor at the Medical College of Wisconsin who is researching the use of digital multimedia to enhance prematurity counseling;
Ruitang Deng, Ph.D., an associate professor of biomedical and pharmaceutical sciences at the University of Rhode Island's College of Pharmacy who is leading a study focused on cholestatis and preterm birth;
Wendy Kuohung, M.D., an associate professor of obstetrics and gynecology at Boston University School of Medicine and a director of the reproductive endocrinology and infertility program at Boston Medical Center who is conducting research on progesterone effects on the oral microbiome and impact on preterm birth;
Donna Lambers, M.D., a Maternal Fetal Medicine specialist and director of perinatal research at TriHealth in Cincinnati, Ohio, who is researching urine metabolic profiling by mass spectrometry of pregnant women at risk for preterm birth;
Ramkumar Menon, Ph.D., an assistant professor in the department of obstetrics and gynecology at the University of Texas-Galveston who is conducting studies on feto-maternal exosome signaling in parturition.
We try to carefully choose web sites, which we believe are useful and meet our high standards for the accuracy and utility of information. However, because web site design and content can change so quickly, we cannot guarantee the standards of every web site to which we link. Likewise, we are not responsible for the content of any non-ACOG site. We also cannot guarantee the privacy policies of these other sites and suggest you check the privacy policies of those sites directly. Should questions arise, please contact the granting organization directly.